EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Oncodesign Precision Medicine (ALOPM) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Oncodesign Precision Medicine €0.26, price €0.31, upside -16.7%, quality 77 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · FR

OP Thin data Sep 23, 2026

Oncodesign Precision Medicine

ALOPM · PA

Great Company, Expensive PriceHigh Quality, but the stock trades above estimated Fair Value.

!Fair value €0.2581 · Overvalued (−17%)
✓Quality 77/100
!Weak Growth (revenue 5y −43.2 %/yr)
✓Low debt
✓Ranks above peers (9/10)
✓Wide moat 85/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 11 out of 100
Watch Oncodesign Precision Medicine for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€3.68 €0.2000 Fair Value €0.2581 Mar 2007 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range €0.2000 – €3.68 · fair‑value band €0.1803 – €0.3353 · the €0.3100 price screens above the €0.2581 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Oncodesign Precision Medicine in your weekly email

Every Wednesday you see whether Oncodesign Precision Medicine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Oncodesign Precision Medicine, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease.

Show more

Oncodesign Precision Medicine, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine was founded in 1995 and is based in Dijon, France.

Stock analysis

Oncodesign Precision Medicine (ALOPM) currently trades at €0.3100, while our model-based Fair Value estimate is €0.2581, implying the stock looks roughly 20.1% overvalued today.

Show more

Valuation

Bull case: the Earnings-Based group reads highest at a median of €2.39 per share, and 9 of the 10 models we run sit above the €0.3100 price.

Bear case: the Asset-Based group reads lowest at €1.86, and 1 of the 10 models stay below the price. Evidence for this calculation is low.

Scenario range: €0.1803 (bear) to €0.3353 (bull), the price of €0.3100 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 77/100 (high quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Oncodesign Precision Medicine reported revenue of €261K in FY2025 versus €3.8M in FY2021, a compound −48.9%/yr. Reported net income was €5.5M in FY2025.

Key figures

Market cap €5.6M · P/E ratio 1.0 · P/S ratio 21.7 · EPS (TTM) €0.3000 · Net margin 302% · Return on equity 204% · Return on assets (EBIT) −26.2% · Operating margin −380%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 63% below its 52-week high and 55% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −17%, ALOPM screens richer than that median.

Fair Value models

Bear €0.1803 Fair Value €0.2581 Bull €0.3353
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.2203 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
ROIC Compounder €2.78 €3.33 €3.92 72
EPV €2.78 €3.27 €3.69 71
Residual Income €2.42 €2.70 €4.16 70
All 10 models by family
Earnings-Based
Graham-Dodd €1.95 €2.39 €2.69 67
EPV €2.78 €3.27 €3.69 71
Multiples
P/E Multiple €4.74 €6.32 €7.90 63
P/S Multiple €0.0400 €0.0500 €0.0600 58
P/B Multiple €3.66 €4.89 €6.11 55
EV/EBIT €5.18 €7.01 €8.84 66
Asset-Based
NCAV (Graham) €1.39 €1.86 €2.77 54
Economic Profit
Residual Income €2.42 €2.70 €4.16 70
ROIC Compounder €2.78 €3.33 €3.92 72
Growth Earnings
Growth-Adj P/E €3.34 €4.78 €6.21 67

Open the full fair value analysis →

Notify me when ALOPM reaches fair value

Put ALOPM on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 77/100

Of which business quality 73 · Market factors (momentum, volatility) 23

Profitability 69
Margins and returns on capital today
Quality Growth 87
Are margins and returns improving?
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 13
Price trend over the last 3–12 months (market factor)
52W Momentum 9
Distance to the 52-week high (market factor)
Net Issuance 68
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+26.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−68.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−43.2%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−139.8% (2020) → 3,146.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

ALOPM screens 20% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Oncodesign Precision Medicine with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 9/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 77 · Top 25%
Fair Value upside +1% · Above median
Profitability
Return on equity (TTM) 204% · Top 25%
Return on assets 28% · Top 25%
Growth and dividend
Revenue growth 7% · Above median
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 1.0× · Cheapest 25%
P/B 0.13× · Cheapest 25%
P/S (TTM) 3.78× · Cheaper than median
EV/EBITDA 2.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 0
FUTURE (revenue growth)37 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)94 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Oncodesign Precision Medicine · Fair Value
€0.2581 −20%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Oncodesign Precision Medicine Fair Value". https://www.fairvalue-calculator.com/stock/ALOPM

Frequently asked questions

Is Oncodesign Precision Medicine (ALOPM) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €0.2581 versus a price of €0.3100, about −17% upside (overvalued).
What is the fair value of ALOPM?
Our model-based fair value for Oncodesign Precision Medicine is €0.2581 (as of Sep 23, 2026), built from audited fundamentals. The current price: €0.3100.
What is the quality score of ALOPM?
Oncodesign Precision Medicine has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oncodesign Precision Medicine (ALOPM)?
Our model-based price target is the fair value of €0.2581 (as of Sep 23, 2026) from 10 valuation models. Cautious scenario €0.1803, optimistic scenario €0.3353. It is a calculation from audited fundamentals, not an analyst target.
What is the Oncodesign Precision Medicine stock forecast for 2026?
Our models put fair value at €0.2581, about −17% upside versus a price of €0.3100 (overvalued). Cautious scenario €0.1803, optimistic scenario €0.3353. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Oncodesign Precision Medicine (ALOPM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oncodesign Precision Medicine it is €0.2581 per share (as of Sep 23, 2026), against a price of €0.3100. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Oncodesign Precision Medicine stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ALOPM trades above its calculated fair value: price €0.3100, fair value €0.2581, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALOPM?
No. The price is what the market pays today (€0.3100); the fair value is what the company's own numbers justify (€0.2581). For Oncodesign Precision Medicine the two are €0.0519 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oncodesign Precision Medicine worth?
The market values Oncodesign Precision Medicine at about €5.6M (market capitalisation, as of Sep 23, 2026). Per share that is €0.3100; our models calculate a fair value of €0.2581 per share.
What do the bullish and bearish scenarios say about ALOPM?
Our models span a range for Oncodesign Precision Medicine: cautious scenario €0.1803, base €0.2581, optimistic €0.3353 per share (as of Sep 23, 2026, price €0.3100). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALOPM?
Oncodesign Precision Medicine trades at a price-to-earnings ratio of 1.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €0.2581 is built from several models across several years. Other multiples: P/B 0.1, P/S 3.8, EV/EBITDA 2.1.
How solid is the balance sheet of Oncodesign Precision Medicine (ALOPM)?
Balance-sheet figures for Oncodesign Precision Medicine (as of Sep 23, 2026): return on equity 203.9%, debt of 0.12 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is ALOPM from its 52-week high?
Oncodesign Precision Medicine trades at €0.3100, about 63% below its 52-week high of €0.8400 and 55% above the low of €0.2000 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €0.2581 is for.
Which stocks are comparable to Oncodesign Precision Medicine?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oncodesign Precision Medicine stock attractive at the current price?
The data as of Sep 23, 2026: price €0.3100, calculated fair value €0.2581 (−17%), Quality Score 77/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALOPM calculated?
We run Oncodesign Precision Medicine through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.2581, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Oncodesign Precision Medicine itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oncodesign Precision Medicine (ALOPM)?
The closing price on Sep 24, 2026 was €0.3100. Our model-based fair value is €0.2581, about −17% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oncodesign Precision Medicine right now?
A high-quality business (quality 77/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. A fairly wide model range (€0.1803 to €0.3353) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Oncodesign Precision Medicine

How large is the market capitalisation of Oncodesign Precision Medicine (ALOPM)?
The market capitalisation of Oncodesign Precision Medicine is €5.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oncodesign Precision Medicine (ALOPM)?
The price-to-sales ratio of Oncodesign Precision Medicine is 21.7 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oncodesign Precision Medicine (ALOPM)?
Earnings per share at Oncodesign Precision Medicine are €0.3000 (price ÷ EPS = P/E 1.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Oncodesign Precision Medicine (ALOPM)?
The net margin of Oncodesign Precision Medicine is 302% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oncodesign Precision Medicine (ALOPM)?
The return on equity (ROE) of Oncodesign Precision Medicine is 204% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oncodesign Precision Medicine (ALOPM)?
On an EBIT basis the return on assets of Oncodesign Precision Medicine is −26.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oncodesign Precision Medicine (ALOPM)?
The operating margin of Oncodesign Precision Medicine is −380% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oncodesign Precision Medicine (ALOPM)?
Revenue at Oncodesign Precision Medicine is growing +7.4% versus a year earlier (3y avg −68.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Oncodesign Precision Medicine (ALOPM) carry?
The net debt of Oncodesign Precision Medicine is €6.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Oncodesign Precision Medicine in the live analysis

One click puts Oncodesign Precision Medicine on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.